Xspray Pharma: Brief Comment on Recent Newsflow
Redeye notes that Xspray has decided to submit its ANDA application for HyNap-Dasa in early 2021 (previously Q4 2020). We see a rationale for this decision as it enables Xspray to gather a more robust data package for HyNap-Dasa to include in its ANDA application. The new timeline aligns with our current assumptions, and we reiterate our base case of SEK 200 per share.